EpoR-Engineered CAR-T Cells for Selective Expansion Without IL-2 Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell therapies for cancer treatment, such as those using interleukin-2 (IL-2) for T cell expansion, suffer from toxicity and lack of specificity, as IL-2 stimulates all T cells regardless of their anti-tumor capacity, and regulatory T cells dampen immune responses.
Innovation Solution
Development of vectors encoding a mutant erythropoietin (Epo) receptor (EpoRm) with a self-cleaving peptide and a cell surface protein, such as a chimeric antigen receptor (CAR), which enhances T cell proliferation and persistence while maintaining cytotoxicity, using a nucleic acid that includes an Epo receptor with at least 90% sequence identity to specific sequences and a signal peptide like CD8α.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If IL-2 is administered to promote T cell expansion, then T cell proliferation is enhanced, but toxicity increases and specificity is lost as all T cells are stimulated including regulatory T cells
Solution Approach 1:
The patent introduces an intermediary system consisting of a modified Epo receptor (EpoRm) and its ligand Epo. Instead of using IL-2 that directly stimulates all T cells, the system uses EpoRm as a mediator that can be selectively activated. The modified receptor is engineered to respond specifically to Epo, creating a controlled intermediate step between the administered cytokine and the T cell activation, thereby achieving selective proliferation without stimulating regulatory T cells.
Solution Approach 2:
The patent applies local quality by modifying the Epo receptor to be expressed specifically on the surface of adoptively transferred T cells through genetic engineering. This creates a localized property where only the engineered T cells possess the EpoRm receptor, allowing selective stimulation of these specific cells while leaving other T cell populations unaffected. The spatial and cellular specificity is achieved through targeted receptor expression.
2Reliability
If conventional T cell therapy is used, then anti-tumor activity is achieved, but regulatory T cells dampen the immune response reducing efficacy
Solution Approach 1:
The Epo/EpoRm system serves as a selective intermediary that discriminates between different T cell populations. By engineering the EpoRm receptor to be expressed only on the therapeutic T cells and not on regulatory T cells, the system creates a communication channel that selectively benefits the anti-tumor T cells while ignoring the suppressive regulatory T cells, thereby maintaining reliable anti-tumor activity without immune suppression.
3Duration of action of moving object
If a mutant Epo receptor with stop codon in exon 8 is used, then stronger and more durable signals are produced, but receptor stability may be affected
Solution Approach 1:
The patent applies parameter changes by introducing a specific mutation (stop codon in exon 8) in the Epo receptor gene. This genetic parameter modification creates a truncated receptor form (EpoRm) that exhibits altered signaling properties - specifically stronger and more durable signals. The mutation changes the molecular parameters of the receptor, affecting its signaling duration and intensity while maintaining sufficient stability for therapeutic function.
Data Source
AI summary
The present invention relates to a vector encoding a wildtype or truncated form of erythropoietin receptor (EpoR) to promote T cell survival and proliferation. Specifically, it exemplifies a bicistronic vector that expresses a truncated EpoR with an anti-CD19-41 BB-003ζ chimeric antigen receptor (CAR) that has a greater ex vivo expansion than CAR-T cells and demonstrates a significantly higher anti-leukemic activity in vivo. It also describes the method of producing cells expressing said vector and the use of these cells to kill CD19+ tumour cells.